ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,127.79
      1.26%
      US Tech 100
      17,444.80
      2.16%
      Dow Jones
      38,675.68
      1.18%
      Brent Oil
      82.765
      -1.03%
      Bitcoin
      62,804.19
      6.23%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Europe
      5. EU
      6. Argen X SE (ARGX)

      7. Argen X SE (ARGX) News

      ARGX Argen X SE

      358.60
      -4.50 (-1.24%)
      May 03 2024 - Closed
      Delayed by 15 minutes
      Company Name Stock Ticker Symbol Market Type
      Argen X SE ARGX Euronext Ordinary Share
        Price Change Change Percent Stock Price Last Traded
      Upgrade Icon
      -4.50 -1.24% 358.60 11:40:00
      Open Price Low Price High Price Close Price Prev Close
      364.00 357.10 368.80 358.60 363.10
      more quote information »

      Recent News

      Date Time Source Heading
      5/02/202401:00GLOBEargenx to Report First Quarter 2024 Financial Results and..
      4/16/202401:00GLOBEargenx Data Highlight Evidence that VYVGART and VYVGART..
      3/27/202402:00GLOBEargenx Advances Clinical Development of Efgartigimod in..
      3/26/202416:00GLOBEargenx Announces Annual General Meeting of Shareholders on..
      3/26/202402:00GLOBEargenx Announces Approval of VYVGART (efgartigimod alfa) in..
      3/07/202416:01GLOBEargenx Delivers on Promise to Transform Patient Expectations..
      2/29/202401:00GLOBEargenx Reports Full Year 2023 Financial Results and Provides..
      2/26/202401:00GLOBEargenx to Present at Upcoming Investor Conferences
      2/22/202401:00GLOBEargenx to Report Full Year 2023 Financial Results and Fourth..
      2/20/202401:00GLOBEargenx Announces FDA Acceptance of Supplemental Biologics..
      1/18/202401:00GLOBEargenx Announces Approval of VYVDURA® (efgartigimod alfa and..
      1/08/202401:00GLOBEargenx Highlights 2024 Strategic Priorities
      1/02/202401:00GLOBEargenx to Present at 42nd Annual J.P. Morgan Healthcare..
      12/20/202301:00GLOBEargenx Reports Topline Results from ADDRESS Study of..
      11/28/202301:00GLOBEargenx Reports Topline Results from ADVANCE-SC Study of..
      11/16/202307:40GLOBEargenx Announces European Commission Approval of..
      11/01/202302:00GLOBEargenx to Present at Upcoming Investor Conferences
      10/31/202302:00GLOBEargenx Reports Third Quarter 2023 Financial Results and..
      10/24/202301:00GLOBEargenx to Report Third Quarter 2023 Financial Results and..
      9/21/202301:00GLOBEargenx Announces VYVGART (efgartigimod alfa) Authorized for..
      9/15/202301:00GLOBEargenx Announces Positive CHMP Opinion for Subcutaneous..
      8/30/202301:00GLOBEargenx to Present at Upcoming Investor Conferences
      7/27/202301:00GLOBEargenx Reports Half Year 2023 Financial Results and Provides..
      7/24/202316:30GLOBEargenx announces closing of global offering
      7/20/202301:00GLOBEargenx to Report Half Year 2023 Financial Results and Second..
      7/19/202317:58GLOBEargenx announces full exercise of underwriters’ option to..
      7/18/202321:30GLOBEargenx raises $1.1 billion in gross proceeds in a global..
      7/17/202316:01GLOBEargenx announces launch of proposed global offering
      7/17/202301:00GLOBEargenx Reports Positive Topline Data from ADHERE Study of..
      6/30/202309:39GLOBEargenx and Zai Lab Announce Approval of VYVGART®..
      6/20/202318:12GLOBEargenx Announces U.S. Food and Drug Administration Approval..
      6/20/202301:00GLOBEargenx Initiates Second Cohort of Phase 2 ARDA Study of..
      5/31/202301:00GLOBEargenx to Present at Upcoming Investor Conferences
      5/04/202301:00GLOBEargenx Reports First Quarter 2023 Financial Results and..

      Your Recent History

      EU
      ARGX
      Argen X
      Delayed Upgrade Clock